Targeted Oncology4h
Reviewing RCC Treatment Choices After Progression With IO/TKI
During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations ...
Targeted Oncology4h
Navigating RCC Treatment Choices After Progression With IO/TKI
During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations ...
MPR10h
Nemvaleukin/Pembrolizumab Combo Fails to Meet Endpoint in Ovarian Cancer Trial
Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.